Charles Flexner

14.3k total citations · 3 hit papers
181 papers, 10.8k citations indexed

About

Charles Flexner is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Charles Flexner has authored 181 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Infectious Diseases, 99 papers in Virology and 46 papers in Epidemiology. Recurrent topics in Charles Flexner's work include HIV/AIDS drug development and treatment (109 papers), HIV Research and Treatment (93 papers) and HIV/AIDS Research and Interventions (56 papers). Charles Flexner is often cited by papers focused on HIV/AIDS drug development and treatment (109 papers), HIV Research and Treatment (93 papers) and HIV/AIDS Research and Interventions (56 papers). Charles Flexner collaborates with scholars based in United States, United Kingdom and South Africa. Charles Flexner's co-authors include Bernard Moss, Bruce D. Walker, Richard E. Chaisson, Robert F. Siliciano, Joel E. Gallant, Roy M. Gulick, Thomas C. Quinn, Karen Chadwick, Franco Lori and Theodore C. Pierson and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Charles Flexner

176 papers receiving 10.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1999 1.6k citations Charles Flexner, Thomas C. Quinn et al. profile →
HIV-Protease Inhibitors

1998 675 citations Charles Flexner profile →
Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

2022 162 citations Daniel R. Kuritzkes, Charles Flexner et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles Flexner United States	51	5.7k	5.3k	2.4k	1.9k	1.5k	181	10.8k
Carlo Federico Perno Italy	56	8.0k 1.4×	6.9k 1.3×	3.5k 1.5×	1.3k 0.7×	2.5k 1.6×	558	13.4k
S. Mallal Australia	59	4.8k 0.8×	4.3k 0.8×	2.4k 1.0×	3.8k 2.0×	2.0k 1.3×	296	14.5k
Richard B. Pollard United States	50	3.7k 0.6×	3.7k 0.7×	3.8k 1.6×	2.9k 1.5×	1.3k 0.8×	268	10.4k
Katherine Luzuriaga United States	44	6.4k 1.1×	2.9k 0.6×	2.1k 0.9×	2.2k 1.1×	1.1k 0.7×	116	10.1k
Paul Deutsch United States	38	4.5k 0.8×	4.5k 0.8×	1.4k 0.6×	1.1k 0.6×	1.9k 1.3×	64	8.6k
Ann C. Collier United States	65	9.1k 1.6×	9.1k 1.7×	3.3k 1.4×	1.4k 0.7×	956 0.6×	256	14.9k
Stephen A. Spector United States	67	7.6k 1.3×	6.5k 1.2×	7.9k 3.3×	2.5k 1.3×	1.5k 1.0×	319	16.2k
Ronald J. Bosch United States	51	6.1k 1.1×	6.8k 1.3×	2.0k 0.8×	2.0k 1.1×	1.1k 0.7×	222	10.9k
Michael A. Polis United States	43	3.5k 0.6×	4.3k 0.8×	2.9k 1.2×	2.8k 1.5×	656 0.4×	143	8.6k
Shinichi Oka Japan	45	4.3k 0.7×	3.2k 0.6×	2.8k 1.2×	1.4k 0.7×	1.0k 0.7×	475	8.1k

Countries citing papers authored by Charles Flexner

Since Specialization

Citations

This map shows the geographic impact of Charles Flexner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Flexner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Flexner more than expected).

Fields of papers citing papers by Charles Flexner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Flexner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Flexner. The network helps show where Charles Flexner may publish in the future.

Co-authorship network of co-authors of Charles Flexner

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Flexner. A scholar is included among the top collaborators of Charles Flexner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Flexner. Charles Flexner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Flexner, Charles, et al.. (2025). Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement. The Journal of Infectious Diseases. 232(3). 607–611.

Wang, Han, Maya K. Monroe, Feihu Wang, et al.. (2023). Constructing Antiretroviral Supramolecular Polymers as Long-Acting Injectables through Rational Design of Drug Amphiphiles with Alternating Antiretroviral-Based and Hydrophobic Residues. Journal of the American Chemical Society. 145(39). 21293–21302. 8 indexed citations

Rajoli, Rajith K. R., Henry Pertinez, Lalitkumar K. Vora, et al.. (2023). Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans. Pharmaceutics. 15(12). 2709–2709. 5 indexed citations

Nachman, Sharon, Claire L Townsend, Elaine J. Abrams, et al.. (2019). Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities. The Lancet HIV. 6(8). e552–e558. 25 indexed citations

Bollinger, Robert C., Chloe L. Thio, Mark Sulkowski, et al.. (2019). Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. The Lancet HIV. 7(6). e443–e448. 30 indexed citations

Zheng, Lu, Babafemi Taiwo, Rajesh T. Gandhi, et al.. (2014). Factors Associated With CD8+ T-Cell Activation in HIV-1–Infected Patients on Long-term Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(2). 153–160. 26 indexed citations

Crawford, Keith W., John Spritzler, Robert C. Kalayjian, et al.. (2010). Age-Related Changes in Plasma Concentrations of the HIV Protease Inhibitor Lopinavir. AIDS Research and Human Retroviruses. 26(6). 635–643. 29 indexed citations

Lee, Lawrence, et al.. (2010). Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers. Antiviral Therapy. 15(2). 275–279. 8 indexed citations

Bakshi, Rahul P., Fayez M. Hamzeh, Ian Frank, et al.. (2007). Effect of Hydroxyurea and Dideoxyinosine on Intracellular 3′-Deoxyadenosine-5′-triphosphate Concentrations in HIV-Infected Patients. AIDS Research and Human Retroviruses. 23(11). 1360–1365. 4 indexed citations

10.

Gulick, Roy M., Zhaohui Su, Charles Flexner, et al.. (2007). Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211. The Journal of Infectious Diseases. 196(2). 304–312. 195 indexed citations

11.

Wilkin, Timothy, Zhaohui Su, Daniel R. Kuritzkes, et al.. (2007). HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211. Clinical Infectious Diseases. 44(4). 591–595. 131 indexed citations

12.

Gruttola, Victor De, Charles Flexner, Jonathan Schapiro, et al.. (2006). Drug Development Strategies for Salvage Therapy: Conflicts and Solutions. AIDS Research and Human Retroviruses. 22(11). 1106–1109. 8 indexed citations

13.

Back, David, David M. Burger, Charles Flexner, & John G. Gerber. (2005). The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes. 39(Supplement 1). S1–S23. 50 indexed citations

14.

Nettles, Richard E., Tara L. Kieffer, Joseph Cofrancesco, et al.. (2005). Psychological Distress and Physical Pain Appear To Have No Short-Term Adverse Impact on Plasma HIV-1 RNA Levels in Patients on Successful HAART. HIV Clinical Trials. 6(5). 262–271. 2 indexed citations

15.

Frank, Ian, Ronald J. Bosch, Susan A. Fiscus, et al.. (2004). Activity, Safety, and Immunological Effects of Hydroxyurea Added to Didanosine in Antiretroviral-Naive and Experienced HIV Type 1-Infected Subjects: A Randomized, Placebo-Controlled Trial, ACTG 307. AIDS Research and Human Retroviruses. 20(9). 916–926. 21 indexed citations

16.

Kresina, Thomas F., Charles Flexner, Jacqueline F. Sinclair, et al.. (2002). Alcohol Use and HIV Pharmacotherapy. AIDS Research and Human Retroviruses. 18(11). 757–770. 64 indexed citations

17.

Lucas, Gregory M., Charles Flexner, & Richard D. Moore. (2002). Directly Administered Antiretroviral Therapy in the Treatment of HIV Infection: Benefit or Burden?. AIDS Patient Care and STDs. 16(11). 527–535. 47 indexed citations

18.

Flexner, Charles. (2002). HLA B57 and abacavir hypersensitivity.. PubMed. 14(3). 5–5. 2 indexed citations

19.

Raines, Charles, Charles Flexner, Eugene Sun, et al.. (2000). Safety, Tolerability, and Antiretroviral Effects of Ritonavir-Nelfinavir Combination Therapy Administered for 48 Weeks. JAIDS Journal of Acquired Immune Deficiency Syndromes. 322–328. 6 indexed citations

20.

Moss, Bernard, Thomas R. Fuerst, Charles Flexner, & Ambros W. Hügin. (1988). Roles of vaccinia virus in the development of new vaccines. Vaccine. 6(2). 161–163. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact